#biotech

Several biotechnology companies have recently announced substantial layoffs as part of broader restructuring efforts. Agios Pharmaceuticals is cutting over 100 R&D roles, while Ultragenyx is laying off 20% of its workforce to reduce its R&D budget. Molecular Partners plans to reduce its staff by up to 44% to focus on its pipeline. Lenz Therapeutics is also making significant cuts, with 75% of its workforce being let go. These actions reflect a challenging period for the biopharmaceutical sector, with companies re-evaluating priorities and operational strategies.

https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026

Agios Pharmaceuticals is implementing significant workforce reductions within its research and development division. The company aims to eliminate over 100 R&D roles by the end of the year. These cuts are intended to decrease the R&D headcount by more than 35% compared to 2025 levels. The anticipated cost savings from these reductions are projected to be realized in 2027. This strategic move comes as Agios awaits a potential FDA approval for its anemia medicine in sickle cell disease.

Cambridge, Massachusetts

https://www.fiercebiotech.com/biotech/agios-aims-shed-100-rd-roles-year-ahead-hoped-scd-approval

Biotechnology firm Fractyl Health is implementing significant workforce reductions, impacting nearly half of its employees. This strategic decision involves discontinuing its gene therapy program to concentrate on a single product. The company aims to streamline operations and advance its weight maintenance treatment, Revita, toward market approval. These changes are expected to be finalized by next month. Co-founder Jay Caplan will also retire from his executive role.

Burlington, Massachusetts

https://www.masslive.com/business/2026/10/mass-biotech-company-to-lay-off-almost-half-its-staff.html

Several biotechnology companies have recently announced substantial layoffs as part of strategic realignments and cost-saving measures. Enlivex is cutting 60% of its staff, while EyePoint is halving its workforce. Caribou Biosciences is halting pipeline development and laying off employees to seek strategic alternatives. Adecto Pharmaceuticals is shutting down operations entirely due to funding challenges. Foghorn Therapeutics is also reducing its workforce by 40% following a failed collaboration.

https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026

Two Massachusetts-based biotechnology companies, Adecto Pharmaceuticals and Aviceda Therapeutics, have announced they are ceasing operations. Adecto Pharmaceuticals has officially closed its doors after struggling with fundraising in a risk-averse market. Aviceda Therapeutics is in the process of winding down its operations due to disappointing clinical trial results. Adecto's CEO expressed hope that the company's research could still be advanced. Both companies were developing novel therapeutic treatments.

Boston, Massachusetts

https://www.biospace.com/job-trends/2-massachusetts-biotechs-call-it-quits

Hundreds of workers in Massachusetts' biotechnology sector have been laid off. The third quarter saw substantial job reductions impacting numerous individuals. Sanofi and TScan Therapeutics were responsible for over half of these workforce reductions. These cuts represent a significant event for the regional biotech industry. The full scope of the layoffs is detailed in the article.

Boston, MA

https://www.bizjournals.com/boston/news/2026/10/07/q3-2026-biotech-layoffs.html

Sionna Therapeutics is implementing significant layoffs, reducing its workforce by approximately 46%. This decision follows the failure of its SION-719 cystic fibrosis trial. The company is shifting its focus to a new dual combination therapy. This strategic pivot aims to advance a different NBD1 stabilizer and CFTR corrector. The restructuring is expected to extend the company's cash runway.

Boston, MA

https://www.fiercebiotech.com/biotech/sionna-lays-46-workforce-strategic-shift-after-cystic-fibrosis-trial-fail

Eurofins Diatherix will be closing its lab facility. The company provides molecular diagnostic testing services. These services are for hospitals and physicians. The article does not specify the number of employees affected. Further details are behind a paywall.

Birmingham, Alabama

https://www.bizjournals.com/birmingham/news/2026/09/03/biotech-company-to-close-lab-facility.html

TScan Therapeutics is significantly reducing its workforce by 75% to reallocate resources. The company is pausing its hematological and autoimmune programs to prioritize preclinical solid tumor initiatives. This strategic shift aims to advance its solid tumor pipeline and seek partnerships for its paused programs. The decision was influenced by insufficient capital for ongoing trials and a recent collaboration termination. These changes are expected to extend the company's financial runway.

Waltham, Massachusetts

https://www.fiercebiotech.com/biotech/tscan-axes-75-workforce-make-room-solid-tumor-programs

Biotechnology firm Cellares Corporation is reducing its workforce by 68 employees. These layoffs are occurring at the company's Bridgewater facility. The company stated the cuts are part of a restructuring effort. This move aims to focus resources on existing customer programs. The decision follows the termination of a partnership with a pharmaceutical client.

Bridgewater, New Jersey

https://www.nj.com/business/2026/09/68-nj-workers-to-lose-jobs-after-biotechnology-company-downsizes.html

ArsenalBio is undergoing a significant restructuring, laying off 99 employees to focus on in vivo CAR-T therapy. This strategic shift involves halting development of the company's ex vivo clinical assets. The biotech was once a strong fundraiser, securing substantial investments and partnerships. The company is now seeking new opportunities for its existing technology and assets. This move places ArsenalBio in a competitive field with several established players.

San Francisco, California

https://www.fiercebiotech.com/biotech/arsenalbio-sheds-most-staff-pivot-vivo-car-t

Aura Biosciences is laying off 20% of its staff to concentrate on a single experimental eye cancer treatment. This strategic shift aims to reduce operating costs and extend the company's cash runway into 2029. The company is deprioritizing its bladder cancer program to focus resources on its lead dr-g candidate for choroidal melanoma. This restructuring includes leadership changes and follows a recent increase in authorized common stock. These layoffs are part of a broader trend of workforce reductions within the Massachusetts biotech sector.

Boston, Massachusetts

https://hoodline.com/2026/08/cambridge-eye-cancer-biotech-aura-cuts-20-of-staff-to-fund-late-stage-trial/

Boston-based Aura Biosciences is implementing a significant workforce reduction. The biotechnology company will lay off 20% of its employees. This move is part of a strategic shift to concentrate on ocular oncology. The company anticipates incurring restructuring charges between $2.9 million and $3.2 million. This decision reflects a refocusing of the company's priorities.

Boston, MA

https://www.nbcboston.com/boston-business-journal/boston-biotech-to-cut-20-of-workforce/3996623/

https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026

Massachusetts experienced fewer biotech job cuts. This marks the lowest number since early 2024. Seven life sciences companies were affected. At least 346 positions were eliminated between April and June. Reasons included failed dr-g trials and FDA rejections.

https://www.bizjournals.com/boston/news/2026/07/01/mass-q2-2026-biotech-layoffs.html

Sangamo Therapeutics announced 52 job eliminations. The company entered Chapter 11 bankruptcy protection. These layoffs are a direct result of the bankruptcy filing. A total of 52 positions were affected by this decision. The company is undergoing financial restructuring.

San Francisco, CA

https://www.bizjournals.com/sanfrancisco/news/2026/06/24/bankruptcy-layoffs-sangamo-therapeutics.html

ADC Therapeutics announced a strategic reorganization. This plan includes a 17% reduction in its global workforce. The company expects to save $10 million annually from these cuts. This follows recent safety concerns in a Zynlonta clinical trial. The reorganization aims to focus resources on the Zynlonta franchise.

https://www.fiercepharma.com/pharma/amid-safety-concerns-adc-therapeutics-plots-17-staff-cuts-push-resources-behind-lead-adc

Charles River Laboratories recorded a net loss in the first quarter. The company also disclosed plans to lay off 71 employees. A one-time $118 million charge from asset sales led to the net loss. Without this charge, adjusted earnings per share beat expectations. New CEO Birgit Girshick introduced a strategic framework for future operations.

Wilmington, Massachusetts

https://www.masslive.com/news/2026/05/charles-river-laboratories-posts-loss-amid-dozens-of-layoffs-says-turnaround-on-track.html

Biotech layoffs are slowing in 2026 compared to the previous year. BioNTech announced a major restructuring, eliminating 1,860 jobs. Vistagen reduced its workforce by 20% after a dr-g trial failure. Replimune cut 224 positions following an FDA dr-g rejection. Takeda and Merck also implemented significant job reductions due to various pressures.

https://www.pharmavoice.com/news/biotech-layoffs-pharma-dr-g-jobs/819649/

Biontech plans significant production cuts. This German company will reduce its workforce. Approximately 1,800 staff members will depart. Decreased demand for COVID-19 vaccines drives this decision. Biontech developed its vaccine with Pfizer.

https://medwatch.com/article19266743.ece

Passage Bio will reduce its workforce by 75%. This follows tough feedback from the FDA regarding its lead gene therapy. The FDA did not support a single-arm trial for the PBFT02 candidate. Passage Bio has also launched a strategic review for the company. This review includes exploring options like a merger, sale, or partnership.

Philadelphia, Pennsylvania

https://www.fiercebiotech.com/biotech/passage-launches-strategic-review-and-75-layoffs-after-gene-therapy-path-blocked-fda

Replimune Group Inc. laid off 224 Massachusetts employees last week. These cuts followed the FDA's second rejection of its lead cancer dr-g, RP1. The layoffs occurred across two facilities in Woburn and Framingham. The first wave eliminated 63 positions, followed by 161 additional cuts. Company filings suggest more employee reductions may be finalized soon.

Woburn, Massachusetts

https://www.masslive.com/news/2026/04/200-mass-biotech-employees-were-laid-off-last-week-that-may-only-be-the-beginning.html

Allied Group LLC will lay off 154 employees. This was reported to the Rhode Island Department of Labor and Training. The company offers fulfillment services. It supports life science and biotech companies. Employee separations are scheduled to begin on May 25.

Rhode Island

https://turnto10.com/news/local/allied-group-llc-to-layoff-over-150-employees-in-rhode-island

Less than a year after cutting 25% of its workforce, Bicycle Therapeutics is once again making layoffs. This time, the biotech is set to reduce its workforce by 30%. Because Bicycle had 288 employees at the start of 2026, this means about 86 workers are set to lose their jobs in this round of layoffs.

https://www.nbcboston.com/boston-business-journal/massachusetts-biotech-cuts-30-of-workforce-winds-down-lead-dr-g/3917165/

https://www.fiercebiotech.com/biotech/evotec-reveals-sweeping-800-person-layoffs-more-site-closures-restructuring-rolls

Alltrna, a Flagship Pioneering-backed biotech, recently laid off 19 employees. This marks the company's third workforce reduction. The decision aims to prepare Alltrna for clinical trials of its tRNA dr-g candidate. After the layoffs, 36 staffers remain at the Cambridge, Mass.-based company. Alltrna focuses on developing tRNA medicines for genetic liver diseases.

https://www.fiercebiotech.com/biotech/alltrna-undergoes-third-layoff-round-entering-clinic-cutting-35-jobs

No number out, but cuts have been reported.

https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026

Charles River Closes Maryland Cell Therapy Site, Cuts 20 Jobs

Charles River Laboratories is closing its cell therapy CDMO site in Hanover, Maryland. This closure will result in 20 employee layoffs. The decision is part of a broader company restructuring. Other Charles River facilities will take over client work by mid-2026. The company aims to optimize its business and save $70 million annually by 2026.

https://www.fiercebiotech.com/cro/charles-river-close-cell-therapy-cdmo-site-lay-20-staffers

More biotech companies continue to reduce their workforce, with layoffs stretching into mid-2026, underscoring the sustained pressure facing the sector as funding remains tight and strategic priorities shift.

https://www.biospace.com/biospace-layoff-tracker

A company spokesperson confirmed that the job cuts will impact staff at its San Francisco headquarters as well as remote employees working from Seattle.

https://www.biospace.com/biospace-layoff-tracker

Tessera’s layoffs come amid broader biotech industry adjustments, with the company narrowing its research scope to core gene-editing efforts tied to its partnership with Regeneron and moving other projects

https://www.boston.com/news/business/2026/01/12/somerville-biotech-company-laying-off-35-of-workforce/

Tessera Therapeutics is planning to lay off 90 employees, the Flagship-founded biotech has warned.

In a state layoff notice posted Wednesday, Tessera explained that the workforce reduction will affect employees based in a number of U.S. states starting March 8.

https://www.fiercebiotech.com/biotech/flagship-founded-tessera-plans-lay-90-employees-march

https://globalbiodefense.com/2025/07/03/trump-vance-research-cuts-biotech-warning-2025/

After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron Corporation is scaling back its head count.

https://www.fiercepharma.com/pharma/geron-lay-13-workforce-quest-slash-operating-costs-maximize-rytelo-launch

I heard from my colleagues that there was another round this morning. Anybody else heard about this?

TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.

https://www.fiercebiotech.com/biotech/tscan-lays-30-workforce-halts-phase-1-solid-tumor-t-cell-receptor-trial

Title speaks for itself. There have been some significant departures within Quality leadership recently. Anyone have any insights?

Roche’s Genentech unit is laying off staff at its Bay Area headquarters for at least the third time this year, saying goodbye to 118 employees in a workforce reduction that spans multiple departments.

https://www.fiercebiotech.com/biotech/genentech-says-goodbye-118-employees-third-hq-layoff-round-year

What do you all think? Does that mean imminent layoffs in US/UK?